Company profile for Neurogene

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Neurogene is accelerating development of new genetic medicines to people with devastating neurological diseases and their families. To do this, we are working with experts across the globe to advance a broad pipeline of programs to treat the underlying cause of serious neurological disorders and thereby address the overwhelming need for new therapies. Although the human genome was sequenced for the first time nearly 20 year...
Neurogene is accelerating development of new genetic medicines to people with devastating neurological diseases and their families. To do this, we are working with experts across the globe to advance a broad pipeline of programs to treat the underlying cause of serious neurological disorders and thereby address the overwhelming need for new therapies. Although the human genome was sequenced for the first time nearly 20 years ago, the true genomics revolution is taking place now, providing us with the ability to radically alter rare, genetic disorders. At Neurogene,

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
535 W 24th Street, 5th Floor New York, NY 10011
Telephone
Telephone
1-877-237-5020
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.businesswire.com/news/home/20251113825408/en/Neurogene-Reports-Third-Quarter-2025-Financial-Results-and-Highlights-Recent-Updates

BUSINESSWIRE
13 Nov 2025

https://www.businesswire.com/news/home/20251112150450/en/Neurogene-Reports-Positive-Interim-Data-in-Pediatric-Cohort-from-NGN-401-Gene-Therapy-Trial-for-Rett-Syndrome

BUSINESSWIRE
12 Nov 2025

https://www.businesswire.com/news/home/20251106135659/en/Neurogene-Announces-First-Participant-Dosed-in-Embolden-Registrational-Trial-of-NGN-401-Gene-Therapy-for-Rett-Syndrome

BUSINESSWIRE
06 Nov 2025

https://www.businesswire.com/news/home/20251105674125/en/Neurogene-Announces-Inducement-Grant-Under-Nasdaq-Listing-Rule-5635c4

BUSINESSWIRE
05 Nov 2025

https://www.businesswire.com/news/home/20251009995946/en/Neurogene-Announces-Positive-Regulatory-Update-for-NGN-401-Gene-Therapy-in-Rett-Syndrome-with-Plans-to-Initiate-Dosing-in-Embolden-Registrational-Trial-in-Q4-2025

BUSINESSWIRE
09 Oct 2025

https://www.businesswire.com/news/home/20251008682068/en/Neurogene-to-Participate-in-H.C.-Wainwright-Genetic-Medicines-Virtual-Conference

BUSINESSWIRE
08 Oct 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty